Agenus (NASDAQ:AGEN) Rating Lowered to Hold at Zacks Research

Agenus (NASDAQ:AGEN) was downgraded by Zacks Research from a “strong-buy” rating to a “hold” rating in a report released on Monday,Zacks.com reports.

Separately, Wall Street Zen upgraded shares of Agenus from a “hold” rating to a “buy” rating in a research note on Monday, April 6th. One analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Agenus has a consensus rating of “Hold” and an average price target of $14.50.

Agenus Stock Up 5.5%

Shares of NASDAQ:AGEN opened at $3.44 on Monday. Agenus has a 12 month low of $2.71 and a 12 month high of $7.34. The company’s fifty day simple moving average is $3.72 and its 200 day simple moving average is $3.67. The firm has a market cap of $132.10 million, a price-to-earnings ratio of 2.16 and a beta of 1.60.

Agenus (NASDAQ:AGEN) last issued its quarterly earnings data on Monday, May 11th. The biotechnology company reported $1.02 EPS for the quarter, missing analysts’ consensus estimates of $2.10 by ($1.08). Agenus had a negative return on equity of 29.79% and a net margin of 50.49%.The company had revenue of $33.70 million for the quarter, compared to analyst estimates of $129.50 million. Research analysts expect that Agenus will post 2.1 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Agenus

Several hedge funds have recently modified their holdings of the stock. Redwood Family Wealth LLC bought a new position in shares of Agenus in the 4th quarter valued at about $44,000. Ovata Capital Management Ltd bought a new position in shares of Agenus in the 4th quarter valued at about $97,000. Virtu Financial LLC bought a new position in shares of Agenus in the 4th quarter valued at about $108,000. EP Wealth Advisors LLC bought a new position in shares of Agenus in the 4th quarter valued at about $31,000. Finally, Quadrature Capital Ltd acquired a new position in shares of Agenus during the 4th quarter worth about $54,000. Institutional investors own 61.46% of the company’s stock.

About Agenus

Agenus, Inc (NASDAQ:AGEN) is a clinical-stage immuno-oncology company headquartered in Lexington, Massachusetts. The company focuses on the discovery and development of therapies designed to modulate the immune system’s response to cancer. Leveraging proprietary platforms in checkpoint modulation, vaccine technology and adjuvant systems, Agenus aims to deliver combination regimens that enhance antitumor activity across a variety of solid tumors and hematological malignancies.

Agenus’ pipeline includes monoclonal antibodies targeting immune checkpoints, cytokine-based therapeutics and vaccine candidates built on its engineered heat shock protein (HSP) platform.